MENU
PBE
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
PBE
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for PBE with price predictions
Oct 21, 2026

PBE in upward trend: price rose above 50-day moving average on October 14, 2026

PBE moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 47 of 53 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on PBE as a result. In 76 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for PBE just turned positive on October 15, 2026. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.

The 10-day moving average for PBE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in 258 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 220 of 254 cases where PBE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

PBE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF (PBE) ETF is 30.01B. The market cap for tickers in the group ranges from 746.01M to 236.98B. AMGN holds the highest valuation in this group at 236.98B. The lowest valued company is COLL at 746.01M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF (PBE) ETF was 32%. For the same ETF, the average monthly price growth was 43%, and the average quarterly price growth was 299%. SRPT experienced the highest price growth at 10%, while NVAX experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF (PBE) ETF was 34%. For the same stocks of the ETF, the average monthly volume growth was 40% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 54
Price Growth Rating: 42
SMR Rating: 68
Profit Risk Rating: 68
Seasonality Score: 25 (-100 ... +100)